2025-01-14

复星医药子公司复宏汉霖再度携手Abbott,多款生物药布局新兴市场

2025年1月13日,复星医药子公司复宏汉霖(2696.HK)宣布与Abbott签署许可协议,授予其在69个新兴市场国家和地区独家或半独家开发和商业化公司自主开发的四款生物类似药和一款生物创新药,协议覆盖亚洲、拉丁美洲和加勒比海地区及中东北非。该许可协议是在双方现有肿瘤领域生物类似药合作的基础上进一步深化。

根据新协议,预计到2027年,第一批分子候选物将上市,其余产品待完成临床开发和注册。Abbott将负责合作区域内合作产品的上市注册,并撬动其现有业务的广泛影响力和行业领导地位来推动合作产品的市场推广。作为一家专注于肿瘤、自身免疫疾病及眼科疾病的国际化生物制药公司,复宏汉霖将于其位于上海的GMP认证生产基地生产这些药物。


此次双方扩大合作,致力于令全球患者获得高质量、可负担的先进生物药,进一步兑现双方在新兴市场提供更多先进治疗选择的承诺。

 

复宏汉霖高级副总裁兼首席商务发展官

曹平女士

复宏汉霖很高兴能与Abbott进一步加深合作。Abbott凭借其值得信赖的优质成熟药品、持续的技术创新能力以及完备的本地分销网络,于新兴市场达成稳健增长,已然成为新兴市场医疗领域的领军企业。此次双方再度携手,有力彰显了双方致力于推动全球健康可及性这一共同愿景。我们坚信,通过整合双方的资源与专业技能,我们将为新兴市场提供高效的健康解决方案,进一步提升当地肿瘤治疗的整体水平。

Shanghai, China, January 13, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) ,a subsidiary of Fosun pharma  announced it has entered into product license and supply agreement with Abbott, granting it exclusive or semi-exclusive licenses for the commercialization of four self-developed biosimilars and one innovative biologic in 69 emerging markets in Asia, Latin America and the Caribbean, as well as Middle East and Africa. This agreement builds on an existing collaboration between the two companies for the commercialization of oncology biosimilars.


Under this new agreement, the first molecules are anticipated to be launched in 2027, with some still subject to the completion of clinical development and registration. Abbott will secure the molecule registration in these regions and will launch the products by leveraging its broad presence and leadership position through its existing business. Henlius, a global biologics company focusing on oncology, autoimmune and ophthalmic diseases, will manufacture the medicines in its GMP-approved facility in Shanghai.


The expanded collaboration aims to enhance global access for patients to high-quality, affordable advanced biologics, reinforcing the commitment of both parties to deliver more advanced treatment options in emerging markets.


Ping Cao, Senior Vice President and Chief Business Development Officer of Henlius, said, “Henlius is delighted to reaffirm our collaboration with Abbott, a healthcare leader in emerging markets, realizing consistent growth with its trusted, high-quality established products, continuous technological advancements, and comprehensive local distribution networks. This expanded agreement is a testament of our common focus on expanding access to health, globally. We are confident that by pooling our joint efforts and expertise, we can deliver effective health solutions to emerging markets and improve standards of care for oncology.”